Revolutionizing Cancer Treatments with Precision Radionuclide Therapy
Advancements in Cancer Treatment Technology
Vivos Inc. is making significant strides in the field of cancer treatment. The company has unveiled promising data highlighting the accuracy of its patented Precision Radionuclide Therapy. This approach utilizes specialized delivery systems known as RadioGel and IsoPet to provide targeted radiation therapy for both human and veterinary applications.
Understanding Therapeutic Ratios
The therapeutic ratio is a pivotal factor in cancer treatment, as it measures the amount of radiation directed at a tumor compared to the surrounding healthy tissues. A higher therapeutic ratio is essential because it reduces collateral damage while maximizing tumor destruction. This precision is crucial for effective treatment outcomes.
Clinical Validation and Success Stories
In recent clinical studies, Vivos’ RadioGel technology demonstrated an impressive therapeutic ratio, earning the FDA Breakthrough Device designation. The initial validation process involved comprehensive calculations from top-tier physicists in the field. Now, Vivos has fortified this validation with supporting data from both its animal health division and human clinical trials.
Veterinary Achievements
Dr. Ben Buchanan at Brazos Valley Equine Hospital has successfully utilized RadioGel to treat Ocular Squamous Cell Carcinoma (OSCC) in horses. Extensive treatments were administered, including injections directly into tumors located on the eyelids and corneas. Remarkably, these treatments showed no damage to the surrounding eye tissues, nor were there any adverse effects reported.
Impressive Human Clinical Data
The human clinical trials yielded equally promising results. Cancerous lymph nodes situated near vital structures like the trachea and carotid artery were treated with great efficacy. At the three-month mark post-treatment, these tumors became undetectable through imaging, and no measurable damage to critical structures was noted. Observations from CT/PET scans indicated no radiation exposure in surrounding areas, ensuring patient safety.
Unique Potential in Treating Complex Tumors
Michael K. Korenko, Sc.D., President & CEO of Vivos Inc., remarked on the confidence these findings instill regarding the potential of RadioGel and IsoPet. They offer a unique capability to effectively treat tumors near essential organs, a feature that could significantly increase the addressable market in cancer therapy.
Vivos Inc.'s Commitment to Innovation
Vivos Inc. is dedicated to expanding its therapeutic capabilities through ongoing research and development. The company plans to further validate its findings through domestic animal therapies and international human clinical trials. However, it is important to note that RadioGel is not yet FDA-approved for commercial use in the United States; the data discussed is drawn from an international clinical trial aligning with U.S. standards.
About Vivos Inc.
Vivos Inc. is at the forefront of innovative cancer treatment, specializing in radionuclide delivery platforms such as RadioGel and IsoPet. The company has trademarked the term Precision Radionuclide Therapy to encapsulate its unique treatment approach.
Contact Information
To learn more about Vivos Inc. and its groundbreaking therapies, visit www.VivosInc.com.
Follow Vivos Inc. on X (Twitter): @VivosIncUSA
Media Contact:
Michael K. Korenko, Sc.D.
Email: MKorenko@RadioGel.com
Frequently Asked Questions
What is Precision Radionuclide Therapy?
Precision Radionuclide Therapy is an advanced approach to cancer treatment that delivers targeted radiation to tumors while minimizing damage to surrounding healthy tissues.
What technologies does Vivos Inc. use?
Vivos Inc. utilizes RadioGel for human therapies and IsoPet for veterinary applications to enhance treatment precision.
Why is the therapeutic ratio important?
The therapeutic ratio is crucial because it determines how effectively radiation can target tumors while protecting healthy tissue, reducing side effects, and improving treatment outcomes.
Are there any side effects from treatments using RadioGel?
Clinical studies have shown no measurable side effects or damage to surrounding tissues during treatment with RadioGel.
How can I learn more about Vivos Inc.?
Visit VivosInc.com for more information.
About The Author
Contact Ryan Hughes privately here. Or send an email with ATTN: Ryan Hughes as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.